UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
OMB APPROVAL
OMB Number: 3235-0058
Expires: February 28, 2022
Estimated average burden hours per response ... 2.50
 
SEC FILE NUMBER
333-228183
 
CUSIP NUMBER
98979T 107
 
(Check one):
 
☒ Form 10-K ☐   Form 20-F ☐   Form 11-K  ☐ Form 10-Q ☐   Form 10-D ☐   Form N-SAR ☐   Form N-CSR
 
 
 
 
 
For Period Ended:
April 30, 2019
 
 
 
 
 
☐    Transition Report on Form 10-K
 
 
 
 
 
☐    Transition Report on Form 20-F
 
 
 
 
 
☐    Transition Report on Form 11-K
 
 
 
 
 
☐    Transition Report on Form 10-Q
 
 
 
 
 
☐    Transition Report on Form N-SAR
 
 
 
 
 
For the Transition Period Ended:
 

 
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

APOTHECA BIOSCIENCES, INC.


Full Name of Registrant

 

CANNABIS LEAF INCORPORATED
Former Name if Applicable

 

10901 Roosevelt Blvd., Suite 1000C
Address of Principal Executive Office (Street and Number)

 

Saint Petersburg, Florida 33716
City, State and Zip Code

  1  
 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
ý
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

ý
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

☐
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III — NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The registrant was not, without unreasonable effort or expense, able to file its Annual Report on Form 10Q for the period ended April 30, 2019 . The registrant anticipates that it will file its Form 10-Q within the "grace" period provided by Securities Exchange Act Rule 12b-25.  
 
PART IV — OTHER INFORMATION
 
(1)
 
Name and telephone number of person to contact in regard to this notification
 
 
 
 
 
John Verghese
 
(727)
 
228-3994
(Name)
 
(Area Code)
 
(Telephone Number)
 
 
 
 
 
 
 
 
(2)
 
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
 
Yes ý      No  ☐
 
 
 
(3)
 
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 
Yes ☐      No  ☒
 
 
 
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
.
 
 
 
 
 

 
 
Apotheca Biosciences Inc.

(Name of Registrant as Specified in Charter)

 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
Date: June 14, 2019 By: /s/ John Verghese  
  John Verghese
  Chief Financial Officer